New combo therapy offers hope for advanced bile duct cancer patients
NCT ID NCT07291063
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with advanced bile duct cancer that cannot be removed by surgery. It tests whether adding immunotherapy drugs (anti-PD-1/PD-L1 antibodies) to standard chemotherapy (gemcitabine and cisplatin) is safe and works better at shrinking tumors and delaying cancer growth. About 50 adults will take part, and researchers will monitor side effects and how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Fudan university
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact